The short answer
SOLIS-1 (NCT07575932) is a Phase 2b umbrella study that has enrolled 940 adults with overweight or obesity. It tests PF-08653945, an amylin analogue, and PF-08653944 (berobenatide), alone or in combination, across three separate cohorts, with a primary completion date of 4 August 2027.
Key facts
- Registration
- NCT07575932
- Registered acronym
- SOLIS-1
- Design
- Phase 2b, randomised, double-blind, placebo-controlled, dose-ranging umbrella study
- Enrolment
- 940 (actual)
- Compounds
- PF-08653945 (amylin analogue) and PF-08653944 (berobenatide)
- Cohorts
- 3
- Status
- Active, not recruiting
- Primary completion
- 4 August 2027
- Registry checked
- ClinicalTrials.gov, 21 November 2026
- Sponsor
- Pfizer
What an umbrella study is, and why this one is
The registered title calls SOLIS-1 an umbrella study, which has a specific meaning. A conventional trial answers one question about one intervention. An umbrella study runs several sub-studies under a shared protocol, infrastructure and often a shared control group, so that multiple interventions are evaluated in one operational machine. The savings are real: one set of sites, one data-monitoring committee, one set of eligibility criteria and, above all, participants recruited into a common pool rather than competing trials. The cost is complexity, and the risk is that a shared control group creates comparisons the design was never powered to support.
The three cohorts
Cohort 1 gives PF-08653945 or placebo. Cohort 2 gives PF-08653945 plus PF-08653944, or placebo. Cohort 3 gives PF-08653945 plus PF-08653944, or PF-08653944 alone, or placebo. Read together, that structure lets the sponsor characterise the amylin analogue on its own, the combination, and (in cohort 3 only) the combination against its own GLP-1 component within a randomised comparison. That last point is the one that matters scientifically. A combination that beats placebo tells you very little; a combination that beats its own more established component is the only evidence that adding the second agent did anything.
Research material referenced
Retatrutide 10mg, third-party HPLC tested
What PF-08653945 is
PF-08653945, also written PF'3945 and previously MET-233i, is an amylin analogue engineered for monthly dosing. Its Phase 1 data, reported by Metsera in June 2025, came from a randomised, placebo-controlled, double-blind trial in 80 people with overweight or obesity and without type 2 diabetes, using single doses from 0.15 mg to 2.4 mg and multiple doses from 0.15 mg to 1.2 mg given weekly over five weeks. The reported observed half-life was 19 days and mean placebo-subtracted weight loss reached 8.4% at day 36 after five weekly 1.2 mg doses. Gastrointestinal adverse events were described as mild, dose-dependent and mostly confined to the first week.
Why the pharmacokinetics are the point
The stated rationale for combining these two specific molecules is not that amylin and GLP-1 agonism are complementary; that argument applies to cagrilintide with semaglutide and to petrelintide programmes too. It is that the amylin analogue's exposure profile after multiple doses matched that of the GLP-1 agonist. Two drugs can only share a fixed-dose monthly injection if their concentration-time curves are compatible; otherwise one is at trough while the other is at peak, and the ratio the trial tested is not the ratio the patient receives. Combinability here is a pharmacokinetic achievement before it is a pharmacological one, and most coverage skips that part.
What SOLIS-1 will and will not settle
It is a dose-ranging Phase 2b study. Its job is to select doses and characterise tolerability well enough to design Phase 3, not to establish efficacy for registration. Primary completion is August 2027. Nothing in it will be pivotal evidence, and neither compound is licensed anywhere. Neither is supplied on this site.
Frequently asked questions
How is an umbrella study different from a platform trial?
The terms overlap and are used loosely. An umbrella study typically evaluates several interventions within one disease under a shared protocol. A platform trial adds the ability to enter and drop arms over time against a shared, often adaptive, control. A basket trial does the opposite of both: one intervention across several diseases. SOLIS-1 is registered as an umbrella study with three fixed cohorts.
Does combining amylin with GLP-1 work?
There is Phase 3 evidence for one such combination (cagrilintide with semaglutide) and Phase 1 and 2 evidence for others. Whether it works for this particular pair is what SOLIS-1 exists to find out. The general principle being established for one pair does not transfer to another pair, because the answer depends on the specific molecules, their exposure profiles and their dose ratios.
What does 940 participants buy in Phase 2b?
Enough to compare several dose levels against placebo with reasonable precision, and to see common adverse events. It is not enough to characterise uncommon safety signals, which is why Phase 3 obesity programmes run into the thousands.
Continue researching
Related guides and reference material.
Primary sources & clinical trials
Published papers, trial registrations, regulator pages and company announcements. Links open the original.
- TrialSOLIS-1 registry record (NCT07575932)clinicaltrials.gov
- TrialMET233 and MET097 combination study registry record (NCT06924320)clinicaltrials.gov
- RefMetsera: positive Phase 1 data for once-monthly amylin candidate MET-233i, 9 June 2025biospace.com
- RefPfizer completes acquisition of Metsera, 13 November 2025pfizer.com
Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).
Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.
More Research & Regulatory News articles
- Reading Deal Structure as a Statement About EvidencePfizer paid $65.60 a share for Metsera plus a CVR of up to $20.65 tied to three milestones. That structure encodes how uncertain the buyer thought the data was.
- The Gap Is Smaller Outside the Trial, and It Widens With TimeA 2,396-patient US cohort found a 2.32-point weight difference at six months. The head-to-head trial found 6.5 points at 72 weeks. Both figures are right.
- Which Drug Signals Where, and What That Is WorthA 2026 FAERS analysis compared semaglutide, liraglutide and tirzepatide across gastrointestinal, renal and pancreatic outcomes. The pattern is not uniform.
- Two Phase 3 Trials, 4,700 Participants, and One Missing AcronymStructure Therapeutics dosed the first patients in its aleniglipron Phase 3 programme in July 2026. Both trials are registered; only one carries its own name.
- A Warning Comes Off Three GLP-1 LabelsOn 13 January 2026 the FDA asked manufacturers to remove the suicidal ideation warning from Saxenda, Wegovy and Zepbound, citing 91 randomised trials.